Sino Medical has released its 2026 half-year performance forecast, expecting net profit attributable to shareholders of the listed company to reach 50.33 million yuan in the first half, an increase of 36.49 million yuan compared with the same period last year, representing a year-on-year growth of 263.66%. The company stated that the profit growth was mainly driven by the continued steady volume expansion of products in the coronary business segment, as well as significant sales growth of new products in the neurological business segment.
Sino Medical Sciences Technology InExpects net profit to rise 263.66% YoY driven by volume expansion and new product sales growth.